Tissue resources are essential for studies of outcome markers, predictive markers, molecular epidemiology, and discovery of novel molecular therapeutic targets. Their importance is even more apparent In this evolving era of molecular imaging as well as high throughput technologies. The immense value of clinical biological sample collection is therefore readily apparent. Methods of harvesting, storage, and appropriate quality control are also vitally important to assure the high tissue quality required for advanced technology platforms. Finally, significant investments of skill, time and money have gone in to build these resources, and consideration and planning is given towards access and distribution of samples, so that these holdings have value-added as local, regional, national, and international resources. The Path Core will provide expertise and leadership for SPORE investigators in all areas of tissue acquisition and analysis. Human tumors are . highly complex because of inter-and intra-tumoral heterogeneity. The development and implementation of highly innovative technologies for the simultaneous assessment of multiple antigens/genes at the tissue level will also be an integral part of this Core, underscoring its constant drive to improve upon molecular pathologic analysis. Specifically, the technologies we have developed and are continuing to refine as well as sophisticated imaging technologies, will allow the identification of multiple antigens/genes. In summary, this Pathology Core is a critical component of the lung SPORE effort, and is uniquely positioned to characterize the morphologic phenotype of lung neoplasms, relate these findings to their molecular characterization, and rapidly advance our understanding of human tumors of the lung. The understanding produced by these investigations should ultimately lead towards the development of novel therapeutic strategies for this heterogeneous group of diseases within the funding period of this SPORE.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
VanderLaan, Paul A; Rangachari, Deepa; Majid, Adnan et al. (2018) Tumor biomarker testing in non-small-cell lung cancer: A decade of change. Lung Cancer 116:90-95
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Ji, Xuemei; Bossé, Yohan; Landi, Maria Teresa et al. (2018) Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun 9:3221
Guo, Yichen; Zhang, Ruyang; Shen, Sipeng et al. (2018) DNA Methylation of LRRC3B: A Biomarker for Survival of Early-Stage Non-Small Cell Lung Cancer Patients. Cancer Epidemiol Biomarkers Prev 27:1527-1535
Haines, Eric; Chen, Ting; Kommajosyula, Naveen et al. (2018) Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer. Oncotarget 9:31572-31589
Wang, Zhaoxi; Wei, Yongyue; Zhang, Ruyang et al. (2018) Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. EBioMedicine 32:93-101
Torous, Vanda F; Rangachari, Deepa; Gallant, Benjamin P et al. (2018) PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option? J Am Soc Cytopathol 7:133-141
Ferreiro-Iglesias, Aida; Lesseur, Corina; McKay, James et al. (2018) Fine mapping of MHC region in lung cancer highlights independent susceptibility loci by ethnicity. Nat Commun 9:3927
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M et al. (2017) Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes. Lung Cancer 106:17-21
Rangachari, Deepa; VanderLaan, Paul A; Shea, Meghan et al. (2017) Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ?50% Expression in Lung Adenocarcinoma. J Thorac Oncol 12:878-883

Showing the most recent 10 out of 263 publications